Indications of Pegcetacoplan-Empaveli and its scope of clinical application

Pegcetacoplan (Pegcetacoplan) is a new complementC3 inhibitor that directly inhibits the complement cascade reaction and blocks C3 activation, thereby reducing red blood cell membrane damage and inflammatory responses. Clinically, PegTac has been approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare complement-mediated hemolytic disorder characterized by susceptible red blood cell destruction, leading to anemia, increased risk of thrombosis, and multisystem complications. By inhibiting C3-mediated hemolysis, PegTac not only reduces irregular hemolysis and anemia, but also improves the quality of life and long-term prognosis of PNH patients.

In addition to PNH, pegatuck has also shown significant potential in kidney disease. It is suitable for patients aged 12 years and above to treat C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) by inhibiting the over-activated complement system, reducing proteinuria and delaying the decline of renal function. Such patients are usually accompanied by glomerular inflammation and fibrosis caused by excessive complement activation, and may develop chronic renal insufficiency or even end-stage renal disease in the long term.

In clinical application, Pegtak is mainly administered through subcutaneous injection, which can maintain stable blood concentrations. At the same time, compared with traditional complement inhibitors, it reduces dependence on downstreamC5, making the treatment more comprehensive. PNH patients usually receive treatment while routinely monitoring hemoglobin levels, hemolysis indicators, and liver and kidney functions to evaluate efficacy and safety. Patients with C3G or IC-MPGN need to regularly monitor urinary protein, serum complement levels and renal function indicators in order to adjust the treatment plan.

Overall, the indications of PegTac cover complement-mediated diseases in the field of blood and kidney, providing new treatment options for patients with PNH and specific C3-mediated glomerular diseases. Especially when traditional treatments have poor efficacy or risk of drug resistance, its clinical application value has been significantly improved.

Reference materials:https://empaveli.com/